在早期的双击DLBCL中非典型的中枢神经系统复发:对监测和预防的临床影响
Priyanka Anvekar1, Sheikh Abdullah2, Anil Ananthaneni3
1Internal Medicine, LSU Health Shreveport, Shreveport, Louisiana, USA priyankaanvekar.pa@gmail.com.
BMJ case reports
|October 17, 2025
概括
本案例研究详细介绍了一名患有丸扩散大B细胞淋巴瘤 (DLBCL) 的患者,该患者实现了缓解,但后来经历了中枢神经系统 (CNS) 复发. 采用了新的治疗方法,引发了对高风险DLBCL患者中枢神经系统预防的疑问.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 神经学 神经学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种常见的非霍奇金淋巴瘤.
- 丸DLBCL是一种罕见且具有攻击性的表现.
- 中枢神经系统 (CNS) 复发是DLBCL的一个重要问题,即使有预防措施.
研究的目的:
- 要呈现一个阶段IE丸DLBCL的病例.
- 讨论DLBCL中中枢神经系统复发的管理.
- 探索中枢神经系统预防的必要性和高风险DLBCL患者的新疗法策略.
主要方法:
- 一个中年男性患者的病例报告.
- 在最初的疾病中使用DA-EPOCH-R化疗和放射治疗.
- 随后使用MATRix疗法治疗中枢神经系统复发.
主要成果:
- 初始丸DLBCL的成功5年缓解.
- 孤立的中枢神经系统复发的发展.
- 用MATRix疗法治疗中枢神经系统复发的方法.
结论:
- 丸DLBCL可以在中枢神经系统中复发,需要仔细监测.
- 在高风险患者中,中枢神经系统预防的有效性需要进一步研究.
- 新型疗法和分子标记物可能会改善DLBCL患者的治疗结果.
更多相关视频
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
560
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
30.4K
相关概念视频
Therapeutic Drug Monitoring: Overview and Classification
306
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
306
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
